DarioHealth Corp. (DRIO)
NASDAQ: DRIO · IEX Real-Time Price · USD
1.430
-0.030 (-2.05%)
At close: May 31, 2024, 4:00 PM
1.420
-0.010 (-0.70%)
After-hours: May 31, 2024, 6:42 PM EDT
DarioHealth Revenue
DarioHealth had revenue of $19.04M in the twelve months ending March 31, 2024, down -28.58% year-over-year. Revenue in the quarter ending March 31, 2024 was $5.76M, a -18.51% decrease year-over-year. In the year 2023, DarioHealth had annual revenue of $20.35M, a decrease of -26.41%.
Revenue (ttm)
$19.04M
Revenue Growth
-28.58%
P/S Ratio
2.25
Revenue / Employee
$69,000
Employees
276
Market Cap
42.79M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.35M | -7.30M | -26.41% |
Dec 31, 2022 | 27.66M | 7.14M | 34.82% |
Dec 31, 2021 | 20.51M | 12.94M | 170.76% |
Dec 31, 2020 | 7.58M | 17.00K | 0.22% |
Dec 31, 2019 | 7.56M | 165.00K | 2.23% |
Dec 31, 2018 | 7.39M | 2.22M | 43.02% |
Dec 31, 2017 | 5.17M | 2.37M | 84.45% |
Dec 31, 2016 | 2.80M | 1.98M | 240.58% |
Dec 31, 2015 | 823.00K | 772.00K | 1,513.73% |
Dec 31, 2014 | 51.00K | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cutera | 196.64M |
CareCloud | 113.02M |
Daxor | 34.67M |
Ocuphire Pharma | 19.01M |
Daré Bioscience | 2.82M |
Clene | 620.00K |
DRIO News
- 18 days ago - DarioHealth Reports First Quarter 2024 Financial and Operating Results - PRNewsWire
- 26 days ago - DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th - PRNewsWire
- 5 weeks ago - Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes - PRNewsWire
- 6 weeks ago - Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution - PRNewsWire
- 7 weeks ago - Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health - PRNewsWire
- 2 months ago - Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health - PRNewsWire
- 2 months ago - DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results - PRNewsWire
- 2 months ago - DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH - PRNewsWire